Market News & Trends
Cytovation Initiates Clinical Development Program for First-in-Class Agent for Tumor Immunotherapy
Cytovation AS recently announced the first patients have been treated in a Phase I clinical study with CyPep-1, a novel therapeutic agent being developed as…
NapaJen Pharma & Astellas Pharma Establish Research Collaboration for Discovery & Development of Novel Oligonucleotides
NapaJen Pharma, Inc. recently announced it has entered into a research collaboration with Astellas Pharma Inc. for the discovery and development of novel oligonucleotide therapeutics.…
Innovate Biopharmaceuticals Reports Financing to Initiate Phase 3 Clinical Trial
Innovate Biopharmaceuticals, Inc. recently announced it closed its previously announced equity financing, resulting in gross proceeds of $9.7 million. The company expects to use the…
Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis
Nicox SA recently announced the initiation of a Phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being…
BioAegis Therapeutics Completes Enrollment in Phase 1b/2a Dose-Ranging Safety Study
BioAegis Therapeutics Inc. recently announced it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy for patients…
Altimmune Announces Positive Results From NasoVAX Extension Study
Altimmune, Inc. recently announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated…
SunGen Pharma & Athenex Pharmaceutical Division Announce Injection Product Launch
SunGen Pharma recently announced the launch of Busulfan Injection, the second product launch through their joint venture Peterson Athenex with Athenex Pharmaceuticals. The ownership of…
CURE Pharmaceutical Expands US DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant
CURE Pharmaceutical recently announced it has broadened its US Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both…
Imugene Announces First Patient Dosed in Open-Label Phase 2 Study
Imugene Limited recently announced dosing of the first patient in an open-label, randomized multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the…
Santhera Completes Patient Enrollment in Phase IV Long-term Study
Santhera Pharmaceuticals recently announced it has completed patient enrollment in the ongoing Phase IV study (LEROS) with Raxone (idebenone) for the treatment of Leber's hereditary…